Despite the current good progress in the treatment of NSCLC at the time of writing, FDA-approved therapeutics are EGFR, ALK, ROS1, BRAFV600E, MET, RET, NTRK, KRASG12C, HER2 and PD-1 molecular abnormalities [176] (Figure 2). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.